Investor Relations

Conversion Right Triggered on OPKO 3.0% Convertible Senior Notes more »

Phase 3 Data Supporting Rayaldee™ As a Treatment for Secondary Hyperparathyroidism in Chronic Kidney Disease to be Presented at NKF 2015 Spring Clinical Meetings more »

OPKO Investee SciVac Ltd. Enters into Transaction with Levon Resources more »

OPKO Lab Receives Accreditation From College of American Pathologists more »

SEC Filings

  
Filing Description Date Filed Sorted Descending Size View  
4 frost, phillip md et al Apr 17, 2015 31.0 KB View HTML View PDF View XLS  
4 frost, phillip md et al Apr 13, 2015 31.6 KB View HTML View PDF View XLS  
4 frost, phillip md et al Apr 10, 2015 33.2 KB View HTML View PDF View XLS  
4 frost, phillip md et al Apr 9, 2015 30.8 KB View HTML View PDF View XLS  
4 frost, phillip md et al Apr 8, 2015 29.3 KB View HTML View PDF View XLS  
4 frost, phillip md et al Apr 7, 2015 29.7 KB View HTML View PDF View XLS  
4 frost, phillip md et al Apr 3, 2015 28.7 KB View HTML View PDF View XLS  
4 frost, phillip md et al Apr 2, 2015 29.7 KB View HTML View PDF View XLS  
8-K current report Apr 2, 2015 32.9 KB View HTML View PDF View XLS  
4 frost, phillip md et al Apr 1, 2015 40.0 KB View HTML View PDF View XLS  
8-K current report Mar 30, 2015 21.5 KB View HTML View PDF View XLS  
4 kolosov, dmitry Mar 27, 2015 22.6 KB View HTML View PDF View XLS  
4 frost, phillip md et al Mar 26, 2015 29.2 KB View HTML View PDF View XLS  
4 frost, phillip md et al Mar 23, 2015 37.6 KB View HTML View PDF View XLS  
4 logal, adam Mar 19, 2015 22.7 KB View HTML View PDF View XLS  
4 rubin, steven d Mar 19, 2015 22.9 KB View HTML View PDF View XLS  
4 hsiao, jane ph d Mar 19, 2015 22.8 KB View HTML View PDF View XLS  
4 frost, phillip md et al Mar 19, 2015 22.8 KB View HTML View PDF View XLS  
8-K current report Mar 19, 2015 22.1 KB View HTML View PDF View XLS  
4 logal, adam Mar 13, 2015 28.2 KB View HTML View PDF View XLS  
Showing 1-20 of 1666 Page: 1 2 3 4 5 ... 84  Next 20